Skip to content
Home/Companies/Biotech/Amplyx Pharmaceuticals

Amplyx Pharmaceuticals

Biotech·United States·Exited 2021·Held 4yr
Entry
2017
Hold
4yr
Exit
2021

Who owns Amplyx Pharmaceuticals?

Amplyx Pharmaceuticals is an American Biotech company, now owned by Pfizer, which acquired it in 2021 from Lundbeckfonden BioCapital.

Hand-verified · updated 2026-08-18

Open JSON · CC-BY
Lundbeckfonden BioCapital
Investor
Lundbeckfonden BioCapital
Lundbeckfonden BioCapital · 2009 · Life Sciences VC

Key facts

HQUnited States
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
Pfizer
Exit Year
2021

More from Lundbeckfonden BioCapital

Other portfolio companies in the same fund.

QuantumCell
Active
BiotechDenmark· 2025
Kvantify
Active
Deep TechDenmark· 2024
Dania Therapeutics
Active
BiotechDenmark· 2023
Epoqe Pharma
Active
BiotechDenmark· 2021
Lexeo Therapeutics
Exited 2023
BiotechUS· 2021
Notify Therapeutics
Active
BiotechDenmark· 2021

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Amplyx Pharmaceuticals?

Amplyx Pharmaceuticals is now owned by Pfizer, which acquired it in 2021 from Lundbeckfonden BioCapital.

When did Pfizer acquire Amplyx Pharmaceuticals?

Pfizer acquired Amplyx Pharmaceuticals in 2021, buying from Lundbeckfonden BioCapital.

Who did Amplyx Pharmaceuticals sell to?

Lundbeckfonden BioCapital sold Amplyx Pharmaceuticals to Pfizer in 2021 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue